An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. effectiveness

Journal of Child and Adolescent Psychopharmacology

Volumn 19, Issue 5, 2009, Pages 485-492

  Wilens, Timothy E ^a   Hammerness, Paul ^a   Utzinger, Linsey ^a   Schillinger, Mary ^a   Georgiopoulous, Anna ^a   Doyle, Robert L ^a   Martelon, Marykate ^a   Brodziak, Kerry ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE; PLACEBO;

ADD ON THERAPY; ADOLESCENT; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; BRIEF PSYCHIATRIC RATING SCALE; CHILD; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RATING SCALE; SCHOOL CHILD; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PROPYLAMINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 70449090681     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2008.0125     Document Type: Article

References (44)

1. Adler LA, Reingold LS, Morrill MS, Wilens TE: Combination pharmacotherapy for adult ADHD. Curr Psychiatry Rep 5:409-4015, 2006.
2. Ambrosini PJ: Historical development and present status of the schedule for affective disorders and schizophrenia for schoolage children (K-SADS). J Am Acad Child Adolesc Pyschiatry 39:49-58, 2000.
3. American Psychiatric Assocaition: Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington (DC), American Psychiatric Association Press, 1994.
4. Barkley RA, Grodzinsky G, DuPaul GJ: Frontal lobe functions in attention deficit disorder with and without hyperactivity: A review and research report. J Abnorm Child Psychol 2:163-188, 1992.
5. Biederman J, Mick E, Faraone S: Normalized functioning in youths with persistent ADHD. Pediatrics 133:544-551, 1998.
6. Biederman J, Monuteaux M, Seidman L, Doyle AE, Mick E, Wilens T, Ferrero F, Morgan C, Faraone SV: Impact of executive function deficits and ADHD on academic outcomes in children. J Consult Clin Psychol 5:757-766, 2004.
7. Brown TE: Atomoxetine and stimulants in combination for treatment of attention-deficit=hyperactivity disorder: Four case reports. J Child Adolesc Psychopharmacol 1:129-136, 2004.
8. Carlson G, Dunn D, Kelsey D, Ruff D, Ball S, Ahrbecker L, Allen AJ: A pilot study of augmenting atomoxetine with methylphenidate: Safety of concomitant therapy in children with attention-deficit=hyperactivity disorder. Child Adolesc Psychiatry Ment Health 1:10, 2007.
9. Denckla MB: Executive function, the overlap zone between attention deficit hyperactivity disorder and learning disabilities. International Pediatrics 4:155-160, 1989.
10. DuPaul G: The ADHD rating scale: Normative data, reliability, and validity. Unpublished manuscript of the University of Massachusetts Medical School, 1990.
11. DuPaul G, Power T, Anastopoulos A, Reid R: ADHD rating scale IV: Checklists, Norms, and Clinical Interpretation. New York, Guilford Press, 1998.
12. Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J: Metaanalysis of the efficacy of methylphenidate for treating adult attention deficit hyperactivity disorder. J Clin Psychopharmacol 1:24-29, 2004.
13. Faries D, Yalcin I, Harder D, Heiligenstein J: Validation of the ADHD rating scale as a clinician administered and scored instrument. J Atten Disord 2:107-115, 2001.
14. Fischer M, Barkley RA, Edelbrock CS, Smallish L: The adolescent outcome of hyperactive children diagnosed by research criteria: II. Academic, attentional, and neuropsychological status. J Consult Clin Psychol 5:580-588, 1990. (Pubitemid 20356000)
15. Gioia G, Isquith PK, Guy S, Kenworthy L: BRIEF: Behavior Rating Inventory of Executive Function. Odessa (Florida), 2000. Gioia GA, Isquith PK, Retzlaff PD, Espy KA: Confirmatory factor analysis of the Behavior Rating Inventory of Executive Function (BRIEF) in a clinical sample. Child Neuropsychol 4:249-257, 2002.
16. Goldman L, Genel M, Bezman R, Slanetz P: Diagnosis and treatment of attention-deficit=hyperactivity disorder in children and adolescents. JAMA 14:1100-1107, 1998.
17. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S, American Academy of Child and Adolescent Psychiatry: Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2 (Suppl):26S-49S, 2002.
18. Grodzinsky G, Diamond R: Frontal lobe functioning in boys with attention deficit hyperactivity disorder. Dev Neuropsychol 4:427-445, 1992.
19. Gutgesell H, Atkins D, Barst R, Buck M, Franklin W, Humes R, Ringel R, Shaddy R, Taubert K: Cardiovascular monitoring of children and adolescents receiving psychotropic drugs. American Heart Association, Inc 99:979-982, 1999.
20. Halperin J. Conceptualizing, describing, and measuring components of attention: A summary. In: Attention, Memory, and Executive Function. Edited by Lyon G, Krasnegor N. Baltimore: Paul H Brooks, 1996, pp 119-137.
21. Hammerness P, Georgiopoulos A, Doyle R, Utzinger L, Schillinger M, Martelon M., Wilens TE. An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and Pharmacokinetics. J Child Adolesc Psychopharmacol 19:493-498, 2009.
22. Hart EL, Lahey BB, Loeber R, Applegate B, Frick PJ: Developmental change in attention-deficit hyperactivity disorder in boys: A four-year longitudinal study. J Abnorm Child Psychol 6:729-749, 1995.
23. Hazell PL, Stuart JE: A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry 8:886-894, 2003.
24. Kurlan R: Treatment of ADHD in children with tics: A randomized controlled trial. Neurology 17:527-536, 2002.
25. Loney J, Kramer J, Milich RS: The hyperactive child grows up: Predictors of symptoms, delinquency and achievement at follow-up. In: Psychosocial Aspects of Drug Treatment for Hyperactivity. Edited by Gadow K, Loney J. Boulder (Colorado): Westview Press, 1981, pp 3-11.
26. Loney J, Klahn M, Kosier T, Conboy J: Hyperactive boys and their brothers at 21: Predictors of aggressive and antisocial outcomes. In: Prospective Studies of Crime and Delinquency. Edited by van Dused KT, Mednick SA. Hingham (Massachusetts): Kluwer=Nijhoff, 1983, pp 181-207.
27. Lyon GR. The need for theoretical clarity in the study of attention, memory, and executive function. In: Attention, Memory, and Executive Function. Edited by Lyon GR, Krasnegor N. Baltimore: Paul H. Brooks Publishing, 1996, pp 3-11.
28. Mahone EM, Cirino PT, Cutting LE, Cerrone PM, Hagelthorn KM, Hiemenz JR, Singer HS, Denckla MB: Validity of the behavior rating inventory of executive function in children with ADHD and=or Tourette syndrome. Arch Clin Neuropsychol 7:643-662, 2002.
29. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T: Atomoxetine in the treatment of children and adolescents with attention-deficit=hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics 5:E83, 2001.
30. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil CJ, Newcorn JH, Sallee FR, Sangal R, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D: Once-daily atomoxetine treatment for children and adolescents with ADHD: A randomized, placebo-controlled study. Am J Psychiatry 159:1896-1901, 2002.
31. Palumbo DR, Sallee FR, Pelham WE, Jr., Bukstein OG, Daviss WB, McDermott MP: Clonidine for attention-deficit= hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry 2:180-188, 2008.
32. Pataki CS, Carlson GA, Kelly KL, Rapport MD, Biancaniello TM: Side effects of methylphenidate and desipramine alone and in combination in children. J Am Acad Child Adolesc Psychiatry 32:1065-1072, 1993.
33. Pennington BF, Ozonoff S: Executive functions and developmental psychopathology. J Child Psychol Psychiatry 1:51-87, 1996.
34. Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS, McCracken JT, Swanson JM, Lopez M: The Texas Children's Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit= hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 6:642-657, 2006.
35. Rapport M, Denney C, DuPaul G, Gardner M: Attention deficit disorder and methylphenidate: Normalization rates, clinical effectiveness, and response prediction in 76 children. J Am Acad Child Adolesc Psychiatry 6:882-893, 1994.
36. Schachar R, Tannock R, Marriott M, Logan G: Deficient inhibitory control in attention deficit hyperactivity disorder. J Abnorm Child Psychol 4:411-437, 1995.
37. Seidman LJ, Biederman J, Faraone SV, Weber W, Ouellette C: Toward defining a neuropsychology of ADHD: Performance of children and adolescents from a large clinically referred sample. J Consult Clin Psychol 1:150-160, 1997.
38. Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, Clevenger W, Davies M, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March JS, Newcorn JH, Owens EB, Pelham WE, Schiller E, Severe JB, Simpson S, Vitiello B, Wells K, Wigal T, Wu M: Clinical relevance of the primary findings of the MTA: Success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 2:168-179, 2001.
39. Vriezen ER, Pigott SE: The relationship between parental report on the BRIEF and performance-based measures of executive function in children with moderate to severe traumatic brain injury. Child Neuropsychol 4:296-303, 2002.
40. Wilens T: Mechanism of action of agents used in ADHD. J Clin Psychiatry Suppl 8:32-37, 2006.
41. Wilens TE: Effects of methylphenidate on the catecholaminergic system in attention-deficit=hyperactivity disorder. J Clin Psychopharmacol 3(Suppl 2):S46-S53, 2008.
42. Wilens TE, Spencer T. The stimulants revisited. In: Child and Adolescent Psychiatric Clinics of North America 9. Edited by Stubbe C. Philadelphia, Saunders, 2000, pp 573-603.
43. Wilens TE, Spencer TJ, Biederman J, Wozniak J, Connor DE: Combined pharmacotherapy: An emerging trend in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 1:110-112, 1995.
44. Wilens T, Biederman J, Spencer T. Attention deficit hyperactivity disorder. Annu Rev Med 53:113-131, 2002.